Kawasaki disease is an autoimmune like disease preferentially attacking children younger than 5 years old. Early and successful detection within the first 10 days of fever onset is critical for disease treatment. If left untreated, almost 20% to 25% of the patients with KD may develop severe coronary artery aneurysms, making KD the leading cause of acquired heart disease in young children.
To date, no molecular diagnosis methods for Kawasaki disease are available for clinical usage. Thus, this innovation product will provide an opportunity for early diagnosis and treatment. The result was accepted for published on Journal of Allergy and Clinical Immunology, SCI IF: 14.110, ranking 1/26 in Allergy）and National Innovation Award.
We have developed clinically applicable miRNA-Chip. We envision the markets can be extend to countries such as China and Japan.
Authorized cooperation. R & D cooperation
InnoZone Booth No. A049